Co-Diagnostics Q4 2023 GAAP EPS $(0.50) Misses $(0.20) Estimate, Sales $3.555M Miss $3.625M Estimate
Co-Diagnostics Q4 2023 GAAP EPS $(0.50) Misses $(0.20) Estimate, Sales $3.555M Miss $3.625M Estimate
联合诊断2023年第四季度GAAP每股收益（0.50）未达到预期（0.20）美元，销售额355.5万美元未达到362.5万美元的预期
Co-Diagnostics (NASDAQ:CODX) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.20) by 150 percent. The company reported quarterly sales of $3.555 million which missed the analyst consensus estimate of $3.625 million by 1.93 percent. This is a 153.75 percent increase over sales of $1.401 million the same period last year.
Co-Diagnostics（纳斯达克股票代码：CODX）公布的季度亏损为每股0.50美元，比分析师普遍预期的0.20美元（0.20美元）低150％。该公司公布的季度销售额为355.5万美元，比分析师普遍预期的362.5万美元低1.93％。这比去年同期的14.01亿美元销售额增长了153.75％。